Medical Research Collaborative, LLC ("MRC") is proud to offer the following data partnering service to investment firms and other accredited investors. Our Data Partners will benefit from exclusive access to the MRC brain trust, including all comprehensive research reports on targeted biotechnology and pharmaceutical companies identified as possessing outsized return-for-the-risk value. Both long and short-plays will be covered, with a slight bias towards long-plays as predominant (~60%). However, before identifying a play as possessing intrinsic upside value, MRC will probe its prospects from all angles, seeking to refute its bullish thesis, first. If after such a deluge the target company has passed all tests, then we will consider it vetted and the potential upside price targets of its stock much more reliable or possibly even understated.
Our goal is to locate and extract value in the healthcare sector wherever we may find it. And in another sense, a bearish report can also save a firm significant AUM by identifying risks the firm may not have considered in a given equity, and possibly gone long its stock otherwise. A penny saved truly is a penny earned—and nowhere is that more true than in the world of investing, where every dollar saved is another that you may use to obtain ROI.
MRC's valuation model identifies what is termed "expected value" (EV). EV may be derived by calculating the upside and downside potential of a given stock, and then using the odds of either occurring as a determinant of positive or negative value. The EV is expressed as a percentage, which over many runs will equate with the ROI. Entering high-EV trades/investments will result in significant ROI over the medium-long term—but it is imperative that the odds of either outcome and the upside/downside potential is ascertained as accurately as possible. That is what separates market outperformance from underperformance, and what makes MRC's informatics ultimately valuable. Please click here for an example of a real-time EV scenario.
As part of our commitment to MRC Data Partners, we will provide updates and analyses relating to all target companies covered, as well as any ensuing activism on an ongoing basis. This will include the following:
- Consultation on the content of any/all MRC reports*
- Derivations of appropriate position-sizing based on risk:reward assessments
- Patent litigation developments (PACER), and our analysis of the same
- Detailed analysis of new clinical trial results/acquired assets
- Notification of upcoming catalysts, especially as they draw near, with price targets ascribed to various outcomes
- Positive and negative developments involving direct competitors
- Planned/ongoing regulatory submissions of target companies
- Analysis of briefing documents, should there be an AdCom, and our odds of +/- vote
- Analysis of all SEC filings as they occur, with any deviations to prior filings identified and elaborated upon
- Any citizen petitions filed by MRC before they are submitted
- Any and all complaints filed with SEC/FTC/FDA/DOJ, as well as the divulging of ongoing email dialogue
- Some macro analysis on the overall healthcare sector, including potential headwinds and tailwinds, as well as technical indicators in the IBB and XBI.
- The occasional identification of high risk/reward trade scenarios
- Quick but thorough analysis of healthcare plays that have recently experienced a binary event, but are "hung up" in massive trading volume and unable to "break out." Notable examples being CPXX at $7, AMRN at $9, AGRX at $1.20, RETA ay $140, and KRTX at $30.
*Inclusive for initial five data partners only, up to 4 hrs/Q. Data partnering service subscriptions also increase in price beyond the first five partners, with a 3-yr fixed rate per partner; thus, early comers are rewarded. Our Data Partner service will also cap out at 20 partners. As we organically grow, we may in the future accept further partners.
Currently (as of 11/2019), a typical salary for a healthcare buy side analyst with moderate experience is approx. $150,000 - $200,000/yr, with a bonus component typically offering around 90% - 100% of the base salary, and with managers of course earning more. Greater experience and a good track record can yield over $350,000/yr, not including bonuses. A given year's expenditures for a few analysts and a manager could easily eclipse $1.5 - $2 million. Our data partnering service provides an equivalent work load with an even higher level of analysis, but for a fraction of the cost, potentially greatly improving your firm's bottom line.
At this time, there are two well-vetted and highly competent analysts working with MRC, not including the CEO/President of MRC, who also performs the role of full-time analyst as well as manager.
Price Tiering per Quarter by Data Partner Queue:
1 - 5: $21,750/Q; $250/hr. consultation rate (4 hrs./Q gratis)
6 - 10: $28,250/Q; $300/hr. consultation rate
11 - 15: $34,750/Q; $350/hr. consultation rate
16 - 20: $41,250/Q; $400/hr. consultation rate
Subscription fees are payable by quarter, and the service may be canceled at any time (however, MRC will commit to the above pricing for a 3-yr term, unless the data partner cancels their subscription). Minimum commitment by MRC of 200-pages (~500 words/pg. single spaced; will avg. 350-400 words/pg. due to charts, tables, etc.) of comprehensive analysis per quarter included in contract, with failure to meet this commitment resulting in a gratis quarter (partial analyses will be presented as proof of quota, with note of caution at top in red font that such is incomplete and not yet vetted). This will encompass anywhere from one to eight or more companies per quarter, depending upon complexity of pipeline/individual drug candidates, IP, competition, regulatory hurdles, catalysts, etc. Our 203-page analysis of Amarin Corp. (which does not include content from any citizen petitions filed) took the CEO of MRC approx. 300 hours to compile, vet, submit for review, edit, and complete. MRC will thus likely often exceed its minimum quota per Q.
The above mentioned report (currently $8,500 list), which exhaustively covers the Vascepa IP, relevant competition and other marketing headwinds, as well as US and EU sales penetration modeling and regulatory discrepancies, will also be included along with a subscription to our data partnering service.
Please note: MRC does not purposefully engage with former insiders/employees of any publicly traded or otherwise investable company, nor close associates/family members of current/former insiders/employees, nor investigators of ongoing/recently completed clinical trials, nor counsel of ongoing litigation cases that may affect the assessment of a healthcare company, nor any other sources outside of current management/directors/IR staff of a company that may advertently or inadvertently share material non-public information (MNPI). MRC deals only with publicly available information or what may be obtained by FOIA request, conversations with management/directors/IR staff of a company, conversations with patients and healthcare providers, conversations with regulators, and Symphony Health Solutions/IMS Health data analytics. Regardless, all non-public information obtained by MRC is submitted to an independent compliance consultant for vetting before the inclusion of such in any manner (even by inference) in an MRC report, or otherwise sharing of it with Data Partners, to help ensure no MNPI is shared. Should an item come to MRC's attention that MRC considers "gray" regarding whether it is MNPI, even after vetting by our consultant, MRC will proactively disseminate it publicly before including it in any manner in an MRC report or otherwise sharing it with Data Partners. Final reports are also submitted to an independent compliance consultant before dissemination to Data Partners.
For questions and further details, or to request a sample Data Partner contract for review, please contact us directly.